In a surprise move, the FDA has named the longtime leader of its oncology department, Richard Pazdur, M.D., as the new director of the Center for Drug Evaluation and Research, which oversees most ...
MedPage Today on MSN
Five leaders in one year: FDA's drug center enters 2026 at a crossroads
The FDA appointed George Tidmarsh, MD, PhD, to be the nation's top drug official in July. The Center for Drug Evaluation and Research (CDER) has since cycled through another two leaders in 5 months.
Amid an FDA shakeup and reports about interference in drug and personnel decisions, Pazdur resigned last month after more ...
One day after the FDA’s new director of the Center for Drug Evaluation and Research (CDER), Richard Pazdur, M.D., informed colleagues of his sudden and unexpected retirement, one of his lieutenants ...
Through our Venable FDA Pulse series, we provide insight into key developments within the Food and Drug Administration (FDA or the Agency), emerging trends, enforcement activity, and other topics ...
Richard Pazdur will retire from the Food and Drug Administration only weeks after being named the head of its main drug review office. A spokesperson for the FDA confirmed that Pazdur, the director of ...
WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has asked Martin Makary, the Commissioner of the U.S. Food and Drug Administration ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. You’re reading the web edition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback